1-3 of 3
Peter Bias
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 2, International, Multicenter, Prospective Clinical Trial of Subcutaneous Tbo-Filgrastim in Pediatric Patients with Solid Tumors Undergoing Chemotherapy

Noah Federman, Monica Desiree Dragomir, Zoryana Kizyma, Vladimir Lebedev, Jelena Roganovic, Peter Bias, Andreas Lammerich, Zipi Roth-Ben Arie, Linglong Zou, Anton Buchner
Journal: Blood
Blood (2017) 130 (Supplement 1): 2271.
https://doi.org/10.1182/blood.V130.Suppl_1.2271.2271
Published: 2017
Journal Articles

GlycoPEGylated Filgrastim XM22 Demonstrates Dose-Dependent Activity in Comparison to Pegfilgrastim in a Dose-Escalating Study in Healthy Volunteers after Body-Weight Dependent Single Dose.

Heinz Lubenau, PhD, Rolf Pokorny, MD, Luis Lopez-Lazaro, MD, Peter Bias, MD, Bruce Wallin, MD, Walter Hinderer, PhD, Anne-Katrin Maly, Michael Seiberling, MD
Journal: Blood
Blood (2007) 110 (11): 4081.
https://doi.org/10.1182/blood.V110.11.4081.4081
Published: 2007
Journal Articles

GlycoPEGylated Filgrastim XM22 Fixed Dose Demonstrates Similar Activity in Comparison to Pegfilgrastim in Healthy Volunteers after Single Administration.

Heinz Lubenau, PhD, Rolf Pokorny, MD, Luis Lopez-Lazaro, MD, Peter Bias, MD, Bruce Wallin, MD, Walter Hinderer, PhD, Anne-Katrin Maly, Michael Seiberling, MD
Journal: Blood
Blood (2007) 110 (11): 4082.
https://doi.org/10.1182/blood.V110.11.4082.4082
Published: 2007